/MYRX

MYRX Stock - Myrexis, Inc.

Q: What is the analyst price target for MYRX?

Analyst price target information is not currently available for MYRX.

Q: What is MYRX's market cap?

Market capitalization information is not currently available for MYRX.

Financial Services|Shell Companies|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

SELL

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MYRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2008

FY2009

FY2010

FY2011

FY2012

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.88

52W High$0.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	N/A	N/A	$185,000	$90,000	$5.46M
Gross Profit	N/A	N/A	$185,000	$90,000	$5.46M
Gross Margin	N/A	N/A	100.0%	100.0%	100.0%
Operating Income	$-11,991,000	$-31,801,000	$-39,350,000	$-48,116,000	$-58,136,000
Net Income	$-11,621,000	$-31,209,000	$-38,708,000	$-46,951,000	$-58,136,000
Net Margin	N/A	N/A	-20923.2%	-52167.8%	-1065.5%
EPS	$-0.39	$-1.18	$-1.52	$-1.91	$-2.42

Company Overview

Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.

Visit Website

Earnings History & Surprises

MYRX

Beat Rate

50%

Last 6 quarters

Avg Surprise

+0.7%

EPS vs Estimate

Beats / Misses

3/3

Last 12 quarters

Latest EPS

$-0.01

Q2 2013

EPS Surprise History

Q2 12

No data

Q3 12

No data

Q3 12

No data

Q4 12

No data

Q4 12

No data

Q1 13

No data

Q2 13

No data

Q2 13

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2013	Jun 30, 2013	—	$-0.01	—	—
Q2 2013	May 10, 2013	—	$-0.11	—	—
Q1 2013	Mar 31, 2013	—	$-0.11	—	—
Q4 2012	Dec 31, 2012	—	$-0.18	—	—
Q4 2012	Dec 31, 2012	—	$-0.18	—	—
Q3 2012	Sep 30, 2012	—	$-0.13	—	—
Q3 2012	Sep 13, 2012	—	$-0.16	—	—
Q2 2012	Jun 30, 2012	—	$-0.17	—	—
Q1 2012	Mar 31, 2012	—	$-0.40	—	—
Q4 2011	Dec 31, 2011	—	$-0.29	—	—
Q4 2011	Nov 9, 2011	$-0.27	$-0.33	-22.2%	✗ MISS
Q2 2011	Jun 30, 2011	—	$-0.31	—	—
Q2 2011	May 10, 2011	$-0.55	$-0.50	+9.1%	✓ BEAT
Q1 2011	Feb 9, 2011	$-0.45	$-0.31	+31.1%	✓ BEAT
Q4 2010	Nov 9, 2010	$-0.51	$-0.40	+21.6%	✓ BEAT
Q2 2010	Jun 30, 2010	—	$-0.31	—	—
Q2 2010	May 17, 2010	$-0.55	$-0.56	-1.8%	✗ MISS
Q1 2010	Feb 16, 2010	$-0.45	$-0.60	-33.3%	✗ MISS
Q3 2009	Sep 30, 2009	—	$-0.44	—	—
Q2 2009	Jun 30, 2009	—	$-0.60	—	—